Fetal Fraction in NIPT: What It Means for Your Test

Fetal fraction is the percentage of cell-free DNA in your blood sample that comes from the pregnancy rather than from you. When you have noninvasive prenatal testing (NIPT), the lab needs enough of that pregnancy-derived DNA to detect chromosomal differences accurately, and most laboratories require a minimum of about 4% fetal fraction to issue a result. If your sample falls below that threshold, you may get a “no call” or inconclusive report, which can be confusing and anxiety-inducing. But fetal fraction is more than just a pass/fail gate for the test; it carries clinical information of its own.

Where the DNA Actually Comes From

A common misconception is that NIPT analyzes DNA shed directly by the fetus. In reality, the cell-free fetal DNA circulating in your blood originates from the placenta, specifically from cells called cytotrophoblasts that line the placental villi. As these cells naturally turn over and die, they release short fragments of DNA into your bloodstream. Research has provided direct evidence of this cytotrophoblastic origin, which also explains why the test can sometimes give misleading results: the placenta’s genetic makeup does not always perfectly match the fetus’s.

This distinction matters because a condition called confined placental mosaicism (CPM) can create a genetic mismatch between the placenta and the baby. In CPM, some cells in the placenta carry a chromosomal abnormality while the fetus is unaffected, or vice versa. One documented case showed a false positive for trisomy 21 and a simultaneous false negative for another condition, all because the mosaicism existed only in the placenta.

Additionally, when a placenta has mosaic cells (say, half the cytotrophoblast cells carry a trisomy and half don’t), the effective fetal fraction for detecting that particular condition drops. If you have an overall fetal fraction of 10% but only half the placental cells are abnormal, the lab is effectively working with just 5% of signal from the trisomic cells.

Why Body Weight Has Such a Big Effect

Of all the factors that influence fetal fraction, maternal weight is one of the strongest and most studied. As body mass index (BMI) rises, fetal fraction drops, and this relationship is consistent across research. Fetal fraction decreases with increasing maternal weight, leading to higher screen failures and “no call” rates in women with obesity.

⁴

The reason is not as simple as “more blood dilutes the fetal DNA.” Research has found that the total amount of cell-free DNA in the blood does not actually differ between normal-weight and obese women. In one study, the median total cell-free DNA concentration was about 82 picograms per microliter for normal-weight women and 92 for obese women, a statistically insignificant difference. Yet fetal fraction dropped significantly as BMI went up.

⁵

So what is going on? The leading explanation is that higher BMI causes more maternal DNA to be released into the bloodstream. Adipose tissue undergoes higher rates of cell death and turnover, flooding the blood with extra maternal DNA fragments. That extra maternal signal essentially drowns out the fetal signal, driving the fetal fraction percentage down without actually reducing the absolute amount of fetal DNA present.

⁶

This also means waiting longer before drawing blood can help, since fetal fraction rises as the placenta grows. But the catch is that women with higher BMIs see a slower weekly increase in fetal fraction. Women with a BMI of 35 or above had a fetal fraction increase of only about 0.1 units per week, compared to roughly 0.3 units per week for women with normal BMIs.

⁷

In practical terms, if you have a higher BMI and your first NIPT draw comes back with low fetal fraction, your provider may suggest a redraw a few weeks later. But because fetal fraction climbs more slowly, there’s no guarantee a second draw will clear the threshold. This is one of the real limitations of the test that patients with obesity should understand going in.

Medications That Can Lower Fetal Fraction

Weight and gestational age get most of the attention, but certain medications can also push fetal fraction down. Anticoagulants, specifically drugs like heparin and enoxaparin (low-molecular-weight heparin), have been linked to significantly lower fetal fractions. In one study, women on anticoagulation had a mean fetal fraction of about 9.3% compared to 11.7% in women not taking those drugs. More strikingly, the rate of inconclusive results was dramatically higher: roughly 17% versus under 3%. Even after adjusting for BMI, gestational age, and fetal sex, anticoagulation use was associated with more than an eight-fold increase in the chance of getting an indeterminate result.

⁸

Interestingly, aspirin did not show the same effect. The mechanism behind anticoagulants’ impact is still being worked out, but one clue from the same study is that total cell-free DNA was much higher in anticoagulated women (about 218 picograms per microliter versus roughly 84 in controls). That suggests the drugs somehow boost the release of maternal DNA, again swamping the fetal signal the way higher BMI does.

⁸

A systematic review found that decreased fetal fraction was also observed with metformin use, elevated cholesterol and triglyceride levels, and certain hemoglobin-related conditions.

⁹

None of this means you should stop your medication for a blood test. If you’re on heparin, there’s usually a good medical reason. But it is worth knowing about if you get an inconclusive NIPT result while on anticoagulation, so you can discuss your options with your provider rather than assuming something is wrong with the pregnancy.

Low Fetal Fraction as a Signal in Itself

A low fetal fraction result is often treated as a simple technical failure, but research suggests it carries its own clinical meaning. Pregnancies that produce a low fetal fraction on NIPT have been associated with higher rates of adverse outcomes. In one study, nearly 60% of women with low fetal fraction experienced adverse perinatal outcomes, compared to about 29% of women with sufficient fetal fraction. Even after adjusting for race and BMI, low fetal fraction was independently associated with roughly two and a half times the odds of an adverse outcome.

¹⁰

Certain chromosomal abnormalities also tend to produce lower fetal fraction because they affect placental size. An average pregnancy with trisomy 13 or trisomy 18 has an expected fetal fraction roughly 63% as high as a chromosomally normal pregnancy, while triploidy of the maternal type can drive fetal fraction down to about 20% of normal levels.

¹¹

A large meta-analysis confirmed this pattern across dozens of studies. Low fetal fraction was associated with about six times the odds of trisomy 13, roughly four and a half times the odds of trisomy 18, about six times the odds of monosomy X, and a staggering 36 times the odds of triploidy. Trisomy 21, by contrast, did not show this pattern; its odds were not elevated in low-fetal-fraction samples.

¹²

The reason trisomy 21 is the exception fits the underlying biology. Trisomy 21 does not tend to produce the same degree of placental underdevelopment that trisomy 13 and 18 do, so the placenta still sheds adequate DNA. When a provider sees a “no call” NIPT result, the conversation should not stop at “the test didn’t work.” It should include a discussion of what might be driving the low fraction and whether further evaluation, such as detailed ultrasound or diagnostic testing, is warranted.

How Labs Measure Fetal Fraction

Not all NIPT platforms measure fetal fraction the same way, and the method used can affect how precise that number is. Some use counting-based approaches, analyzing how many DNA fragments come from specific chromosomes and estimating the fetal contribution statistically. Others use a method based on single-nucleotide polymorphisms (SNPs), which looks at known genetic variants to separate fetal from maternal DNA fragments.

A study evaluating SNP-based measurement in over 106,000 samples found it to be quite accurate, with a standard deviation of 0.42%. Compared against a reference method that counts Y-chromosome fragments in pregnancies carrying male fetuses, the correlation was very high. The authors noted that the SNP-based approach was three to eight times more precise than other NIPT methods, which had standard deviations ranging from 1.3% to 3.4%.

¹³

Why does precision matter? When fetal fraction sits close to the minimum threshold, even small measurement errors can tip a sample from “reportable” to “no call” or vice versa. A platform with wide measurement variability might reject perfectly good samples or, worse, report results from samples that do not actually have enough fetal DNA for a reliable answer. If you’re comparing NIPT providers, this is one of the less-discussed differences worth understanding.

Lab Techniques for Boosting Fetal Fraction

When a sample has borderline fetal fraction, labs have several strategies to try to rescue it. The most promising exploit a physical difference between fetal and maternal DNA: fetal DNA fragments tend to be shorter. By filtering out longer fragments, the lab enriches the remaining sample with a higher proportion of fetal DNA.

In one head-to-head comparison, libraries from blood samples were size-selected on agarose gel to eliminate fragments longer than 160 base pairs. This pushed the mean fetal fraction from 7% to 13%, and no sample in the study had a fetal fraction below 4% after selection.

¹⁴

Research has also explored optimizing the experimental conditions during library preparation. Lower starting concentrations of cell-free DNA and library material, combined with selecting for even shorter fragments (under 140 base pairs), correlated with higher fetal fractions.

¹⁵

An alternative approach is to simply sequence the sample more deeply, reading more DNA fragments to squeeze out a better signal. This works to a point, but it gets expensive fast since sequencing is the costliest step in the NIPT workflow. And the relationship between sequencing depth and accuracy is not linear; at very low fetal fractions, even dramatically increased sequencing will not reliably distinguish a true signal from background noise.

Enrichment techniques have another promising application beyond rescuing low-fraction samples. One group used fetal fraction enrichment to reanalyze positive NIPT results and distinguish true from false positives. After enrichment, fetal fraction in the reanalyzed samples jumped from about 11% to about 27%. Combined with a threshold-based method for estimating how much of the signal was likely from placental mosaicism, this approach reduced false-positive rates by roughly 80 to 89% across the major trisomies.

¹⁶

Blood Collection and Handling Pitfalls

Something as mundane as the blood collection tube and how the sample is handled before reaching the lab can meaningfully affect fetal fraction. When maternal white blood cells in the sample break down, they release large amounts of maternal DNA, diluting the fetal fraction. This is why NIPT draws typically use specialized cell-stabilizing tubes rather than standard blood collection tubes.

¹⁷

Prolonged storage of blood samples for more than 24 hours under less-than-ideal conditions can also reduce fetal fraction, because maternal cells continue to degrade and release their DNA during that time.

For you as a patient, this is mostly out of your hands. But it is worth knowing that if you receive an inconclusive result and your provider suggests a redraw, the cause may have been something as simple as the sample sitting too long in transit, not anything about your pregnancy. It can be reassuring to know that not every “no call” points to a medical issue.

Twin and Higher-Order Pregnancies

Fetal fraction in twin pregnancies behaves differently from singletons in ways that complicate screening. With two placentas contributing DNA (in the case of fraternal twins), the total fetal fraction is generally higher, but what matters for detecting an abnormality in one specific twin is that twin’s individual contribution, which may be low. If one twin’s placenta is smaller or less active, its fetal fraction may sit below the detection threshold while the combined measurement looks adequate.

Labs have developed approaches to estimate fetal fraction in multiple pregnancies using the size distribution of DNA fragments. This size-ratio method has been validated for twins and triplets, and studies show that fetal fraction still rises with gestational age in these pregnancies, as it does in singletons.

¹⁸

The clinical takeaway is that NIPT for twins carries more uncertainty around fetal fraction, and providers should be especially cautious about interpreting results in higher-order multiples. Size selection and enrichment techniques may help here as well.

Why Maternal DNA Can Create False Positives

The fetal fraction question is usually framed as “is there enough fetal DNA?” But the flip side matters too: what is the maternal DNA doing? In some cases, the mother carries harmless copy number variations, small duplications of genetic material on the same chromosome being tested. These duplications can cause extra reads during sequencing that look like they come from fetal trisomy when they do not.

A study examining false-positive NIPT results found that in about 8% of cases, the mother carried a non-pathogenic duplication on the relevant chromosome. The larger the maternal duplication, the higher the Z-score (the statistical signal the lab uses to call a positive result). When the contribution of those extra maternal reads was mathematically removed, every Z-score in the study dropped back to the normal range.

¹⁹

This is a good illustration of why NIPT is a screening test and not a diagnostic one. A positive result is a reason for follow-up, usually amniocentesis or chorionic villus sampling, not a definitive answer. The maternal genome is part of the background signal the lab is trying to see through, and sometimes that background is noisier than expected.

Emerging Approaches Using Epigenetics

Most current methods for estimating fetal fraction rely on either counting chromosomes, looking at SNP patterns, or measuring fragment sizes. Each has limitations, particularly in pregnancies where the fetus’s sex is female (removing the Y-chromosome shortcut) or where the chromosomal status is unknown. Newer research is exploring whether chemical modifications on the DNA itself can help.

Fetal and maternal DNA carry different patterns of methylation, a chemical tag that cells use to control gene activity. Researchers have developed assays that exploit these differences to estimate fetal fraction independently of the fetus’s sex or chromosome count. One group created a methylation-based assay using droplet digital PCR that works without relying on SNPs, sex chromosomes, or ploidy status at all.

²⁰

Another team took a different epigenetic angle, looking at hydroxymethylation patterns rather than standard methylation. Their analysis specifically enriched fetal DNA fragments from the maternal background, and when used to screen for Down syndrome, it achieved perfect accuracy while needing far fewer sequencing reads than conventional whole-genome approaches. The authors reported that accuracy held even at ultra-low sequencing depths of only one million reads, a fraction of what standard methods require.

²¹

These epigenetic approaches are still largely in the research phase, but they point toward a future where fetal fraction estimation is more universally accurate and where the test itself could work well at lower total DNA concentrations. For patients who currently face high no-call rates because of BMI, medications, or twin pregnancy, that future cannot arrive soon enough.